Stock Traders Buy Large Volume of Illumina Call Options (NASDAQ:ILMN)

Illumina, Inc. (NASDAQ:ILMN) was the target of some unusual options trading on Tuesday. Stock investors acquired 15,326 call options on the stock. This represents an increase of 597% compared to the average volume of 2,198 call options.

Illumina Price Performance

Shares of ILMN stock traded up $1.76 during trading hours on Tuesday, hitting $123.48. 1,508,068 shares of the company’s stock were exchanged, compared to its average volume of 2,174,599. The company has a market capitalization of $18.87 billion, a PE ratio of 15.63, a PEG ratio of 2.34 and a beta of 1.42. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina has a 12-month low of $68.70 and a 12-month high of $153.06. The business’s 50 day simple moving average is $100.95 and its 200-day simple moving average is $94.88.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.16 by $0.18. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, equities research analysts anticipate that Illumina will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on ILMN. Daiwa America downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 12th. Weiss Ratings reissued a “sell (d+)” rating on shares of Illumina in a report on Wednesday, October 8th. Daiwa Capital Markets lowered shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price target for the company. in a research report on Tuesday, August 12th. Royal Bank Of Canada set a $124.00 price objective on Illumina in a research note on Tuesday, September 2nd. Finally, Stephens set a $110.00 price target on shares of Illumina and gave the company an “overweight” rating in a research note on Monday, August 4th. Five research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Illumina presently has a consensus rating of “Hold” and a consensus price target of $115.00.

Insider Transactions at Illumina

In other news, Director Scott Gottlieb bought 500 shares of Illumina stock in a transaction dated Monday, November 3rd. The stock was purchased at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the purchase, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. The trade was a 4.16% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.60% of the stock is owned by corporate insiders.

Institutional Trading of Illumina

A number of institutional investors have recently made changes to their positions in ILMN. Assetmark Inc. grew its holdings in Illumina by 10.2% in the third quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after purchasing an additional 96 shares during the period. Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Illumina by 0.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after purchasing an additional 99 shares during the last quarter. Versant Capital Management Inc grew its position in Illumina by 8.9% during the third quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock valued at $130,000 after acquiring an additional 111 shares during the period. Parkside Financial Bank & Trust increased its stake in Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 115 shares during the last quarter. Finally, Archer Investment Corp lifted its stake in shares of Illumina by 12.9% in the 3rd quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock valued at $102,000 after purchasing an additional 123 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.